XTL Biopharmaceuticals Statistics
Total Valuation
XTLB has a market cap or net worth of $5.72 million. The enterprise value is $5.52 million.
Important Dates
The next estimated earnings date is Thursday, April 30, 2026, before market open.
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
XTLB has 881.39 million shares outstanding. The number of shares has increased by 54.39% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 881.39M |
| Shares Change (YoY) | +54.39% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 45.39% |
| Owned by Institutions (%) | 4.18% |
| Float | 294.77M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.91 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.70 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.70
| Current Ratio | 0.70 |
| Quick Ratio | 0.46 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -119.78 |
Financial Efficiency
Return on equity (ROE) is -577.13% and return on invested capital (ROIC) is -329.50%.
| Return on Equity (ROE) | -577.13% |
| Return on Assets (ROA) | -240.56% |
| Return on Invested Capital (ROIC) | -329.50% |
| Return on Capital Employed (ROCE) | 12,742.55% |
| Weighted Average Cost of Capital (WACC) | 8.54% |
| Revenue Per Employee | $96,800 |
| Profits Per Employee | -$630,800 |
| Employee Count | 10 |
| Asset Turnover | 0.62 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -349,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -59.79% in the last 52 weeks. The beta is 0.68, so XTLB's price volatility has been lower than the market average.
| Beta (5Y) | 0.68 |
| 52-Week Price Change | -59.79% |
| 50-Day Moving Average | 2.68 |
| 200-Day Moving Average | 4.06 |
| Relative Strength Index (RSI) | 39.21 |
| Average Volume (20 Days) | 7,187 |
Short Selling Information
The latest short interest is 6,276, so 2.56% of the outstanding shares have been sold short.
| Short Interest | 6,276 |
| Short Previous Month | 3,369 |
| Short % of Shares Out | 2.56% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.67 |
Income Statement
In the last 12 months, XTLB had revenue of $968,000 and -$6.31 million in losses. Loss per share was -$0.01.
| Revenue | 968,000 |
| Gross Profit | -2.25M |
| Operating Income | -5.99M |
| Pretax Income | -6.66M |
| Net Income | -6.31M |
| EBITDA | n/a |
| EBIT | -5.99M |
| Loss Per Share | -$0.01 |
Full Income StatementBalance Sheet
The company has $259,000 in cash and $86,000 in debt, giving a net cash position of $173,000 or $0.00 per share.
| Cash & Cash Equivalents | 259,000 |
| Total Debt | 86,000 |
| Net Cash | 173,000 |
| Net Cash Per Share | $0.00 |
| Equity (Book Value) | -47,000 |
| Book Value Per Share | -0.00 |
| Working Capital | -228,000 |
Full Balance SheetCash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
| Gross Margin | -232.85% |
| Operating Margin | -618.70% |
| Pretax Margin | -687.71% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |